Michelle Krogsgaard

Biosketch / Results /

Michelle Krogsgaard

Associate Professor, Department of Pathology
Perlmutter Cancer Center

Contact Info

Address
522 First Avenue
New York, NY 10016

212/263-9266
Michelle.Krogsgaard@nyumc.org

Research Summary

The goal of the Krogsgaard laboratory is to understand the molecular and cellular events that contribute to T-cell sensitivity to `self' (cancer) antigens. To accomplish this we employ advanced and highly innovative methods that combine state-of-the-art biophysical methods for characterizing protein-protein interactions e.g. surface plasmon resonance (SPR), X-ray crystallography, infrared (IR) and nuclear magnetic resonance (NMR) spectroscopy with imaging methods (single molecule imaging and FRET) and transgenic TCR technologies which makes our research highly interdisciplinary in its nature. Our research is important not only for understanding the activation of signaling pathways important for T cell function but also for the purpose of modulating signaling through the TCR pharmacologically in new and innovative approaches. This is with the purpose of increasing the sensitivity of T-cells in patients with cancer or HIV or decreasing the sensitivity in patients with autoimmune diseases (multiple sclerosis or diabetes). Supported by the Pew Trust, Cancer Research Institute (CRI), The Arthritis Foundation; New York Chapter, American Cancer Society (ACS), NCI/NIH and NIGMS/NIH.

Research Interests

T-cell recognition and sensitivity, cancer immunology, autoimmunity, receptor signaling

The expression quantitative trait loci in immune pathways and their effect on cutaneous melanoma prognosis
Vogelsang, Matjaz; Martinez, Carlos N; Rendleman, Justin; Bapodra, Anuj Bapodra; Malecek, Karolina; Romanchuk, Artur; Kazlow, Esther; Shapiro, Richard L; Berman, Russell S; Krogsgaard, Michelle; Osman, Iman; Kirchhoff, Tomas. The expression quantitative trait loci in immune pathways and their effect on cutaneous melanoma prognosis. Clinical cancer research. 2016 Jan;:?-? (1901132)

Immunologic profile of melanoma brain metastases (MBM) in patients (pts) with prolonged survival
Lui, Kevin P; Silva, Ines EDPires; Weiss, Sarah Ann; Han, Sung Won; Darvishian, Farbod; Pavlick, Anna C; Golfinos, John; Moogk, Duane; Krogsgaard, Michelle; Osman, Iman. Immunologic profile of melanoma brain metastases (MBM) in patients (pts) with prolonged survival [Meeting Abstract]. Journal of clinical oncology. 2015 MAY 20;33(15):?-? (1729542)

Association of melanoma expression of matrix metalloproteinase-23 with blunted tumor immunity and poor responses to immunotherapy.
Moogk, Duane; Li, Tianqi; Lee, Chelsea; Da Silva, Ines Esteves Domingues Pires; Ma, Michelle W; Friedman, Erica Brooke; De Miera, Eleazar Vega-Saenz; Darvishian, Farbod; Scanlon, Patrick; Perez-Garcia, Arianne; Pavlick, Anna C; Bhardwaj, Nina; Christos, Paul J; Osman, Iman; Krogsgaard, Michelle. Association of melanoma expression of matrix metalloproteinase-23 with blunted tumor immunity and poor responses to immunotherapy. [Meeting Abstract]. Journal of clinical oncology. 2015 MAY 20;33(15):?-? (1729922)

Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma
Rendleman, Justin; Vogelsang, Matjaz; Bapodra, Anuj; Adaniel, Christina; Silva, Ines; Moogk, Duane; Martinez, Carlos N; Fleming, Nathaniel; Shields, Jerry; Shapiro, Richard; Berman, Russell; Pavlick, Anna; Polsky, David; Shao, Yongzhao; Osman, Iman; Krogsgaard, Michelle; Kirchhoff, Tomas. Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. Journal of medical genetics. 2015 Jan;52(4):231-239 (1440102)

Tumor infiltrating lymphocyte (TIL) classifications and association with survival in primary melanomas.
Weiss, Sarah Ann; Han, Sung Won; Vogelsang, Matjaz; Krogsgaard, Michelle; Lui, Kevin P; Shapiro, Richard L; Kirchhoff, Tomas; Darvishian, Farbod; Osman, Iman. Tumor infiltrating lymphocyte (TIL) classifications and association with survival in primary melanomas. [Meeting Abstract]. Journal of clinical oncology. 2015 MAY 20;33(15):?-? (1729842)